Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug developer Talon Therapeutics has recruited first patient in a Phase 1 trial of Marqibo (vincristine sulfate liposomes injection).
Subscribe to our email newsletter
The trial aims to assess the pharmacokinetics, safety and activity of the drug in children and adolescents suffering from relapsed or refractory cancer.
The trial is intended to establish the maximum tolerated dose, dose-limiting toxicities, toxicity profile, and pharmacokinetics profile of the drug in children and adolescents with solid tumors or hematologic malignancies.
Additionally, the trial will also assess the tolerability and potential activity of Marqibo in children and adolescents with relapsed or refractory acute lymphoblastic leukemia (ALL) at the pediatric maximum tolerated dose.